Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 9/20 | 0.97 |
| ▸ | CA12 | O43570 | 8/20 | 0.97 |
| ▸ | CA1 | P00915 | 8/20 | 0.97 |
| ▸ | CA7 | P43166 | 8/20 | 0.97 |
| ▸ | CA13 | Q8N1Q1 | 8/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.75 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.75 |
| ▸ | HPGD | P15428 | 5/20 | 0.75 |
| ▸ | CASP1 | P29466 | 3/20 | 0.75 |
| ▸ | CASP7 | P55210 | 3/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | CA2 | P00918 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396102 | 0.98 | CA9 (1.00) | CA9CA12CA1CA7CA13 | |
| SCHEMBL3190311 | 0.98 | CA9 (1.00) | CA9CA12CA1CA7CA13 | |
| SCHEMBL3924718 | 0.86 | CA9 (0.78) | CA9CA12CA1CA7CA13 | |
| SCHEMBL30098746 | 0.86 | CA9 (0.78) | CA9CA12CA1CA7CA13 | |
| Fraxetin SCHEMBL43472 | 0.86 | CA9 (1.00) | CA9CA12CA1CA7CA13 | |
| SCHEMBL4659463 | 0.86 | CA9 (0.77) | CA9CA12CA1CA7CA13 | |
| Fraxetin SCHEMBL30010613 | 0.86 | CA9 (1.00) | CA9CA12CA1CA7CA13 | |
| SCHEMBL30152059 | 0.85 | CA9 (0.75) | CA9CA12CA1CA7CA13 | |
| Fraxidin Methyl Ether SCHEMBL2464275 | 0.84 | CA9 (1.00) | CA9CA12CA1CA7CA13 | |
| SCHEMBL14296936 | 0.81 | CA9 (0.79) | CA9CA12CA1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | TYR, MC1R, MITF | CA9 3115/4885CA12 3697/4885CA1 4178/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | CA9 2685/4885CA12 2789/4885CA1 2367/4885 |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | TYR, MC1R, MITF | CA9 2461/4885CA12 3253/4885CA1 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.